In the next few minutes, you'll learn why Ozempic and Wegovy are actually the same drug, what makes Mounjaro different, what each one is licensed for, and the questions worth asking before any conversation with a clinician.
The Confusion — Same conversation, three different pens
Three names get thrown around every week, Ozempic, Wegovy, Mounjaro, as if they're one thing. They're not. One is two brands of the same molecule. One is a different molecule entirely. None of this is advice on which to take, that's a conversation for your GP or pharmacist. But knowing what each name actually means, and why, makes that conversation a lot easier to have.
One Drug, Two Brands — Semaglutide wearing two different outfits
Ozempic and Wegovy are both semaglutide, the same molecule, made by the same company. The difference is the licence, the pen, and sometimes the dose. Ozempic was approved first, for type 2 diabetes. Wegovy came later, licensed specifically for weight management. Same active ingredient, different paperwork, different box on the pharmacy shelf. It's a bit like the same fabric, cut into two different garments, one for one job, one for another.
Enter Tirzepatide — Mounjaro isn't semaglutide at all
Mounjaro is a different drug altogether, tirzepatide. Not a rebrand, not a variant, a genuinely different molecule from a different company, Eli Lilly rather than Novo Nordisk. The confusion happens because all three get talked about in the same breath, as if they're interchangeable. They're not twins. Semaglutide and tirzepatide share a family resemblance in how they work, but they're built differently, and that difference matters later in this film.
Why Two Names Exist — One molecule, two markets, two licences
Why bother giving one molecule two brand names? Regulation. A licence for diabetes and a licence for weight management are assessed separately, with separate trial data, separate approval processes, even separate pack sizes. Splitting the brand lets a manufacturer market and supply each use case on its own terms. It's not deception, it's how medicines regulation works. But it does mean the name on the box tells you the intended use, not just the ingredient.
Ozempic: The Licence — Built and approved for type 2 diabetes
Ozempic's UK licence is for type 2 diabetes, helping the body manage blood sugar. Any weight loss some people experience on it is a recognised side effect of how the drug works, not the reason it was approved. That's an important distinction, because it shapes who a GP might prescribe it to, and through which pathway. Weight loss as a side effect, and weight loss as a licensed purpose, are two different conversations entirely.
Wegovy: The Licence — The same molecule, a weight-management licence
Wegovy is the same active ingredient, semaglutide, but licensed specifically for weight management in adults meeting certain clinical criteria. It typically involves a different dose range to Ozempic, reflecting the different trial programme behind that licence. This is the one most associated with the wider cultural conversation about weight-loss injections, but the licence itself is narrower and more specific than the headlines suggest.
Mounjaro: Both Licences — Licensed for diabetes and weight management
Mounjaro, tirzepatide, holds licences for both type 2 diabetes and weight management, under the same brand name, unlike the semaglutide split. That's part of why it gets discussed so widely, one name, two approved uses, rather than needing a second brand entirely. It doesn't mean it's stronger or better for either purpose. It means the manufacturer chose to keep one identity across both licensed indications.
Why the Licence Matters — Paperwork shapes the pathway, not just the box
The licence isn't just legal small print. It shapes which pathway a prescription might follow, what monitoring is expected, and how a clinician frames the conversation with you. A drug licensed for diabetes and one licensed for weight management aren't interchangeable just because the underlying molecule is related. This is exactly the kind of detail worth raising directly with a GP or pharmacist, rather than assuming from the brand name alone.
Meet GLP-1 — A gut hormone that talks to your brain
GLP-1 is a hormone your gut naturally releases after eating. It nudges insulin release, slows how quickly your stomach empties, and sends signals to the brain that dial down appetite. It's not exotic, it's part of ordinary digestion, working quietly every time you eat. These drugs are built to mimic that hormone's action, at a level and duration your own body doesn't naturally sustain on its own.
Semaglutide's One Target — A single receptor, engineered to last
Semaglutide is built to act on the GLP-1 receptor alone, but engineered to stay active in the body for about a week, rather than the few minutes the natural hormone lasts. That extended action is the whole innovation, same signal, dramatically longer reach. It's why Ozempic and Wegovy are typically weekly injections rather than something needed daily. One target, one mechanism, stretched out over time.
Meet GIP — A second gut hormone alongside GLP-1
GIP is a separate gut hormone, released alongside GLP-1 after eating, involved in insulin response and fat handling in ways researchers are still mapping fully. For years it was the quieter sibling in metabolic science, less studied than GLP-1. Tirzepatide's arrival is what pushed it into the spotlight, because it's the second receptor that molecule was built to reach, not just the first.
The Dual-Action Molecule — One molecule, two receptors, one signal each
Tirzepatide is engineered to act on both the GLP-1 and the GIP receptors in a single molecule. That's the mechanical difference from semaglutide, which works on GLP-1 alone. The theory is that combining both signals may produce a stronger metabolic response than either working solo. It's a genuine pharmacological distinction, not marketing language, but a mechanism being different isn't the same as a promise about anyone's individual outcome.
Different, Not Better — Mechanism and outcome are separate questions
It's tempting to hear two receptors and assume twice as good. That's not how pharmacology works. Trials comparing the two molecules exist and are still being built on, but individual results vary hugely by person, by dose, by how a drug is used alongside diet and lifestyle. This film isn't the place to rank them by outcome, that comparison, for your specific situation, belongs with a GP or pharmacist who knows your history.
Same Drug, Different Doses — The number on the pen isn't the whole story
Ozempic and Wegovy come in different dose ranges, reflecting their different licensed purposes, even though the active ingredient is identical. This is exactly why dose and brand aren't the same conversation, and why this programme won't get into specific numbers or milligrams. Dosing decisions are clinical ones, made between a patient and a prescriber, based on individual health, not something to work out from a label at home.
What Gets Reported — Nausea and digestive changes, commonly reported
Across this whole class of medication, nausea and other digestive changes are commonly reported, particularly as the body adjusts. That's about as specific as it's useful to be here, because individual experience varies enormously, and how a drug is introduced and monitored is a clinical decision. If anything about how you're feeling on any medication concerns you, that's a direct conversation for your GP or pharmacist, not a video.
The 'Food Noise' Effect — Why food might suddenly feel quieter
One thing widely reported by people on these medications, and genuinely useful to know food-side, is a quieting of what's sometimes called food noise, the constant background hum of thinking about the next meal or snack. Whether or not that applies to you, it's a reminder that appetite has a biological volume dial, not just a willpower one. That's worth knowing regardless of what's in your kitchen cupboard.
No Two Bodies Alike — Response varies person to person, always
Response to any of these medications varies significantly from person to person, by biology, by how the drug is used alongside food and activity, by dose, by time. Nobody, including this programme, can honestly predict what any individual will experience. Be wary of anyone promising a specific number on a specific timeline. The honest answer is always it depends, and your clinician is the one qualified to talk through what it might depend on for you.
Questions Worth Asking — The questions that make the conversation useful
If you're heading into that conversation, useful questions include which licence applies to my situation, what monitoring will happen, what's commonly reported that I should watch for, and how this fits alongside how I eat, not instead of it. None of that is about which drug to choose, that decision sits with you and your prescriber. It's about walking in informed, rather than confused by three names in the news.
My friend's on Mounjaro and I'm on Ozempic, should I ask my doctor to switch?
That's a clinical decision only your GP or pharmacist can make with your history, the coach can help with what you eat day to day. (answer generated by SugarCoach, the AI coach)
General lifestyle education, not medical advice — personal medical decisions belong with your GP or pharmacist.